TY - JOUR AU - Gelderblom, Hans AU - Jones, Robin L AU - Blay, Jean-Yves AU - George, Suzanne AU - von Mehren, Margaret AU - Zalcberg, John R AU - Kang, Yoon-Koo AU - Razak, Albiruni Abdul AU - Trent, Jonathan AU - Attia, Steven AU - Le Cesne, Axel AU - Siontis, Brittany L AU - Goldstein, David AU - Boye, Kjetil AU - Sanchez, Cesar AU - Steeghs, Neeltje AU - Rutkowski, Piotr AU - Druta, Mihaela AU - Serrano, César AU - Somaiah, Neeta AU - Chi, Ping AU - Harrow, Brooke AU - Becker, Claus AU - Reichmann, William AU - Sherman, Matthew L AU - Ruiz-Soto, Rodrigo AU - Heinrich, Michael C AU - Bauer, Sebastian TI - Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. JO - European journal of cancer VL - 192 SN - 0014-2964 CY - Amsterdam [u.a.] PB - Elsevier M1 - DKFZ-2023-01691 SP - 113245 PY - 2023 AB - In the INTRIGUE trial, ripretinib showed no significant difference versus sunitinib in progression-free survival for patients with advanced gastrointestinal stromal tumour (GIST) previously treated with imatinib. We compared the impact of these treatments on health-related quality of life (HRQoL).Patients were randomised 1:1 to once-daily ripretinib 150 mg or once-daily sunitinib 50 mg (4 weeks on/2 weeks off). Patient-reported outcomes were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer-30 (EORTC QLQ-C30) questionnaire at day (D)1, and D29 of all cycles until treatment discontinuation. Change from baseline was calculated. Time without symptoms or toxicity (TWiST) was estimated as the mean number of days without progression, death, or grade ≥3 treatment-emergent adverse events per patient over 1 year of follow-up.Questionnaire completion at baseline was 88.1 KW - Gastrointestinal stromal tumours (Other) KW - Patient reported outcome measures (Other) KW - Protein kinase inhibitors (Other) KW - Quality of life (Other) LB - PUB:(DE-HGF)16 C6 - pmid:37598656 DO - DOI:10.1016/j.ejca.2023.113245 UR - https://inrepo02.dkfz.de/record/278647 ER -